Solid biosciences reports additional preclinical data demonstrating that its novel capsid, aav-slb101, provides superior transduction efficiency and enhanced distribution to skeletal muscle

- aav-slb101 is the capsid used in sgt-003, solid's next-generation duchenne gene therapy, expected to enter the clinic in late-2023 -

SLDB Ratings Summary

SLDB Quant Ranking